The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Verseon unveils new blockchain technology

18 Sep 2018 07:00

RNS Number : 0404B
Verseon Corporation
18 September 2018
 

Press release September 18, 2018

 

Verseon Corporation

("Verseon" or the "Company")

Verseon unveils new blockchain technology

Blockchain initiative will enable medical and pharma companies to fund and accelerate life-saving developments

Fremont, Calif.-Verseon today unveils transformative blockchain technology for tokenized securities, developed by its wholly owned subsidiary, BlockRules Ltd. Since its founding in 2002, Verseon's mission remains to develop disruptive technologies and products that advance global health. As part of this goal, the company is challenging traditional drug development funding models through the process of tokenization of securities.

BlockRules technology supports the sale, launch, and trading of securities on a public blockchain complete with multijurisdictional regulatory compliance integrated and enforced directly on the blockchain. This breakthrough permits fully regulated, secure, and transparent support of securities, including decentralized trading.

Current blockchain technology has the potential to transform the global investment landscape. To accomplish that, token offerings need to comply with existing security regulations if they are to become ubiquitous. The technology developed by BlockRules is designed to overcome these regulatory hurdles.

"We founded Verseon with the goal of developing new technologies to advance the discovery and development of new medicines," said Adityo Prakash, CEO of Verseon. "By democratizing investment access with blockchain technology, we will change the way new medicines and other life-science innovations are funded and how the resulting proceeds are shared."

BlockRules Ltd. plans to offer its technology to innovative companies ready to embrace the rapidly developing blockchain community. By bringing regulatory certainty to the blockchain, BlockRules aims to provide the global investment community with safer and more relevant opportunities for investment.

"Recent advances in the blockchain space have the potential to narrow the gap between innovative companies and investors," said Neil Woodford, founding partner of Woodford Investment Management*. "Verseon's innovations in this space address some of the traditional choke points in capital flow and should lead to a more efficient market."

About BlockRules Ltd.

BlockRules Ltd., a wholly owned subsidiary of Verseon, is a blockchain technology company supporting the sale, launch and trading of securities. By enforcing multijurisdictional regulatory compliance directly on the blockchain, the company facilitates issuance and decentralized trading that is secure, transparent and verifiable. BlockRules Ltd. handles the registration of investor KYC ("know your customer") information for its products and is providing this service to prospective investors at https://www.blockrules.com.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-phase Company is using its proprietary, computational drug discovery platform paired with a comprehensive in-house chemistry and biology workflow to build a growing drug development pipeline. Through its wholly owned subsidiary BlockRules Ltd., Verseon is also pioneering blockchain technology for regulated securities.

 

*Woodford Investment Management is a shareholder in Verseon

 

-Ends-

For further information, please contact

Verseon Corporation

www.verseon.com

Sebastian Wykeham

+1 (510) 225 9000

 

 

Arden Partners (NOMAD and Joint Broker)

 

Ruari McGirr / Maria Gomez De Olea

 +44 (0) 20 7614 5900

 

 

Cantor Fitzgerald Europe (Joint Broker) 

 

Marc Milmo / Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)

 

Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts

 

Simon Vane Percy

+44 (0) 1737 821 890

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLRMLTMBMBBFP
Date   Source Headline
18th Dec 20194:40 pmRNSSecond Price Monitoring Extn
18th Dec 20194:35 pmRNSPrice Monitoring Extension
11th Dec 20198:18 amRNSTender Offer Results & Special Meeting Notice
9th Dec 20197:00 amRNSResult of Special Shareholder Meeting
29th Nov 20199:05 amRNSSecond Price Monitoring Extn
29th Nov 20199:00 amRNSPrice Monitoring Extension
26th Nov 20192:05 pmRNSSecond Price Monitoring Extn
26th Nov 20192:00 pmRNSPrice Monitoring Extension
26th Nov 20197:00 amRNSCancellation of Depositary Interests Facility
25th Nov 20193:02 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSHolding(s) in Company
22nd Nov 201911:23 amRNSUpdate on Tender Offer
21st Nov 20194:40 pmRNSSecond Price Monitoring Extn
21st Nov 20194:35 pmRNSPrice Monitoring Extension
20th Nov 20194:33 pmRNSTransaction in Own Shares
20th Nov 20198:33 amRNSIssue of Debt
20th Nov 20197:30 amRNSProposed Cancellation of Admission to AIM
29th Oct 20197:00 amRNSResult of 2019 AGM
24th Oct 20199:43 amRNSUpdate on Facility Sale-Leaseback
23rd Oct 201911:28 amRNSSale-Leaseback of Verseon's Facility
18th Oct 20193:38 pmRNSAnnouncement of 2019 Annual General Meeting
17th Oct 20196:24 pmRNSHolding(s) in Company
16th Oct 20195:24 pmRNSHolding(s) in Company
30th Sep 20197:00 amRNSInterim Results
1st Aug 20194:40 pmRNSSecond Price Monitoring Extn
1st Aug 20194:35 pmRNSPrice Monitoring Extension
1st Aug 20192:05 pmRNSSecond Price Monitoring Extn
1st Aug 20192:00 pmRNSPrice Monitoring Extension
11th Jul 20193:43 pmRNSHolding(s) in Company
3rd Jul 20197:00 amRNSAdditional Listing & Total Voting Rights
28th Jun 20197:00 amRNSFinal Results
25th Jun 20197:00 amRNSAdditional Listing & Total Voting Rights
4th Jun 20197:00 amRNSVerseon showcases oral DME candidates at BIO 2019
30th Apr 20197:00 amRNSVerseon presents DME candidate at ARVO 2019
4th Apr 20197:00 amRNSAdditional Listing & Total Voting Rights
1st Apr 20194:10 pmRNSNew TIDM and ISIN for Subscription Shares
28th Mar 20197:00 amRNSFurther Update to Admission of Subscription Shares
22nd Mar 20197:00 amRNSUpdate to Admission of Subscription Shares
19th Mar 20197:00 amRNSResult of Subscription & Related Party Transaction
18th Mar 20197:00 amRNSVerseon announces security token offering
15th Mar 201912:00 pmRNSChange of TIDM
4th Mar 20197:00 amRNSAdditional Listing & Total Voting Rights
11th Feb 20197:00 amRNSVerseon presents low bleed PROACs at ISC 2019
4th Feb 20197:00 amRNSFirst participant dosed in Verseon clinical trial
29th Jan 20197:00 amRNSDirectorate Change
8th Jan 201912:00 pmRNSAdditional listing confirmation
3rd Jan 201910:20 amRNSAdditional Listing & Total Voting Rights
27th Dec 20187:00 amRNSAdditional Listing and Total Voting Rights
6th Nov 20187:00 amRNSResult of AGM and changes to the Board
5th Nov 20187:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.